Switching from an anti-TNF monoclonal antibody to soluble TNF-receptor yields better results than vice versa: An observational retrospective study of 72 rheumatoid arthritis switchers

Joint Bone Spine

Volumn 82, Issue 5, 2015, Pages 330-337

  Lequerré, Thierry ^a   Farran, Émilie ^a   Ménard, Jean François ^b   Kozyreff Meurice, Macha ^a   Vandhuick, Thibault ^a   Tharasse, Christine ^b   Pouplin, Sophie ^a   Daragon, Alain ^a   Le Loët, Xavier ^a   Varin, Rémi ^b   Vittecoq, Olivier ^a  

^a INSERM   (France)

^b ROUEN UNIVERSITY HOSPITAL   (France)

Author keywords

Adalimumab; Etanercept; Infliximab; Rheumatoid arthritis; Switching; TNF blocking agent

Indexed keywords

ABATACEPT; ADALIMUMAB; C REACTIVE PROTEIN; CORTICOSTEROID; CYCLIC CITRULLINATED PEPTIDE ANTIBODY; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RHEUMATOID FACTOR; RITUXIMAB; ANTIRHEUMATIC AGENT; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DAS28; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HUMAN; IMMUNOTHERAPY; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; RETROSPECTIVE STUDY; RHEUMATOID ARTHRITIS; TREATMENT DURATION; ANTAGONISTS AND INHIBITORS; ARTHRITIS, RHEUMATOID; TREATMENT OUTCOME; VERY ELDERLY; YOUNG ADULT;

ADALIMUMAB; ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DRUG SUBSTITUTION; ETANERCEPT; FEMALE; HUMANS; INFLIXIMAB; MALE; MIDDLE AGED; RECEPTORS, TUMOR NECROSIS FACTOR; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT;

EID: 84943353228     PISSN: 1297319X     EISSN: 17787254     Source Type: Journal    
DOI: 10.1016/j.jbspin.2015.01.021     Document Type: Article

References (27)

1. Kievit W., Fransen J., Oerlemans A.J.M., et al. The efficacy of anti-TNF in rheumatoid arthritis, a comparison between randomised controlled trials and clinical practice. Ann Rheum Dis 2007, 66:1473-1478.
2. van der Heijde D., Klareskog L., Landewé R., et al. Disease remission and sustained halting of radiographic progression with combination etanercept and methotrexate in patients with rheumatoid arthritis. Arthritis Rheum 2007, 56:3928-3939.
3. Hetland Ml, Christensen I.J., Tarp U., et al. Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: results from 8 years of surveillance of clinical practice in the nationwide Danish DANBIO registry. Arthritis Rheum 2010, 62:22-32.
4. van Vollenhoven R., Harju A., Brannemark S., et al. Treatment with infliximab (Remicade) when etanercept (Enbrel) has failed or vice versa: data from the STURE registry showing that switching tumour necrosis factor alpha blockers can make sense. Ann Rheum Dis 2003, 62:1195-1198.
5. Buch H., Bingham S.J., Bejarano V., et al. Therapy of patients with rheumatoid arthritis: outcome of infliximab failures switched to etanercept. Arthritis Rheum 2007, 57:448-453.
6. Nikas S.N., Voulgari P.V., Alamanos Y., et al. Efficacy and safety of switching from infliximab to adalimumab: a comparative controlled study. Ann Rheum Dis 2006, 65:257-260.
7. Bombardieri S., Ruiz A.A., Fardellone P., et al. Effectiveness of adalimumab for rheumatoid arthritis in patients with a history of TNF-antagonist therapy in clinical practice. Rheumatology (Oxford) 2007, 46:1191-1199.
8. Iannone F., Trotta F., Montecucco C., et al. Etanercept maintains the clinical benefit achieved by infliximab in patients with rheumatoid arthritis who discontinued infliximab because of side effects. Ann Rheum Dis 2007, 66:249-252.
9. Haraoui B., Keystone E.C., Thorne J.C., et al. Clinical outcomes of patients with rheumatoid arthritis after switching from infliximab to etanercept. J Rheumatol 2004, 31:2356-2359.
10. Ang H.T., Helfgott S. Do the clinical responses and complications following etanercept or infliximab therapy predict similar outcomes with the other tumor necrosis factor-alpha antagonists in patients with rheumatoid arthritis?. J Rheumatol 2003, 30:2315-2318.
11. Hjardem E., Ostergaard M., Podenphant J., et al. Do rheumatoid arthritis patients in clinical practice benefit from switching from infliximab to a second tumor necrosis factor alpha inhibitor?. Ann Rheum Dis 2007, 66:1184-1189.
12. Gomez-Reino J.J., Carmona L. Switching TNF antagonists in patients with chronic arthritis: an observational study of 488 patients over a 4-year period. Arthritis Res Ther 2006, 8:R29. Biobadaser group.
13. Hyrich K.L., Lunt M., Watson K.D., et al. Outcomes after switching from one antitumor necrosis factor alpha agent to a second antitumor necrosis factor alpha agent in patients with rheumatoid arthritis: results from a large UK national cohort study. Arthritis Rheum 2007, 56:13-20.
14. Hansen K.E., Hildebrand J.P., Genovese M.C., et al. The efficacy of switching from etanercept to infliximab in patients with rheumatoid arthritis. J Rheumatol 2004, 31:1098-1102.
15. Rémy A., Avouac J., Gossec L., et al. Clinical relevance of switching to a second tumour necrosis factor-alpha inhibitor after discontinuation of a first tumour necrosis factor-alpha inhibitor in rheumatoid arthritis: a systematic literature review and meta-analysis. Clin Exp Rheumatol 2011, 29:96-103.
16. Blom M., Kievit W., Fransen J., et al. The reason for discontinuation of the first tumor necrosis factor (TNF) blocking agent does not influence the effect of a second TNF blocking agent in patients with rheumatoid arthritis. J Rheumatol 2009, 36:2171-2177.
17. Bennett A.N., Peterson P., Zain A., et al. Adalimumab in clinical practice. Outcome in 70 rheumatoid arthritis patients, including comparison of patients with and without previous anti-TNF exposure. Rheumatology (Oxford) 2005, 44:1026-1031.
18. Chatzidionysiou K., Askling J., Eriksson J., et al. Effectiveness of TNF inhibitor switch in RA: results from the national Swedish register. Ann Rheum Dis 2014, 10.1136/annrheumdis-2013-204714.
19. Arnett F.C., Edworthy S.M., Bloch D.A., et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988, 31:315-324.
20. van Gestel A.M., Prevoo M.L., Van't Hof M.A., et al. Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism Criteria. Arthritis Rheum 1996, 39:34-40.
21. Furst D.E., Keystone E.C., Fleischmann R., et al. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2009. Ann Rheum Dis 2010, 69:i2-i29.
22. Smolen J.S., Kay J., Doyle M.K., et al. Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (Go-After study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial. Lancet 2009, 374:210-221.
23. Salgado E., Maneiro J.R., Carmona L., et al. Rheumatoid factor and response to TNF antagonists in rheumatoid arthritis: systematic review and meta-analysis of observational studies. Joint Bone Spine 2014, 81:41-50.
24. Iannone F., Notarnicola A., Lopalco G., et al. Different switching rate of anti-TNF-α drugs in monotherapy and in combination with methotrexate in a cohort of rheumatoid arthritis patients in the real life. Joint Bone Spine 2014, 81:458-459.
25. st anti-TNF: results of the multicenter randomized controlled "ROC" trial. Abstract 1469. Arthritis Rheum 2013, 65:S624.
26. Smolen J.S., Landewé R., Breedveld F.C., et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis 2010, 69:964-975.
27. van Vollenhoven R.F. Switching between antitumour necrosis factors: trying to get a handle on complex issue. Ann Rheum Dis 2007, 66:849-851.